Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious. Within the same tumour, different parts of the HCC can belong to separate molecular sub-groups. In addition, there is currently no validated predictive biomarkers to help clinicians select the best therapy for an individual patient. This challenge poses an urgent, unmet clinical need. To address this, the multi-disciplinary research program Precision Medicine in Liver Cancer across an Asia-Pacific Network (PLANet 1.0) was conceptualized and successfully conducted from 2016-22. The program uncovered novel insights into the highly heterogeneous molecular landscape of HCC and novel mechanisms, including how HCC reverts to fetal forms to escape the body's immunological defence. These investigations will be continued in PLANet 2.0 and in this new phase, the research team will investigate patients receiving best-in-class therapeutics in 2 investigator-initiated clinical studies (AHCC12 and AHCC13), including Atezolizumab plus Bevacizumab (Atezo+Bev) and Yttrium-90, which allows the research team to collect longitudinal, before and after treatment biosamples and clinical data. These clinical studies will serve as proof-of-concept to the study team's translational findings and allow it to uncover predictive biomarkers which will help clinicians to institute more efficacious and personalized treatment in the future. The research team comprises of experts in different complementary fields (epigenomics, genomics, immunomics, metabolomics, proteomics, clinical science and data science) and across different institutions. This allows the team to adopt an integrative approach in understanding the landscape of the HCC tumour micro-environment and biomarkers co-localisation, and their role in tumour evolution and therapeutic response. By adopting a wide spectrum of converging investigations, PLANet 2.0 will identify and validate biomarkers that correlate with clinical outcomes (response, resistance and recurrence).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraża zgodę na udział w badaniu.
- •Pacjent w wieku od 21 do 90 lat.
- •Pacjent z rakiem wątroby, który miał operację usunięcia guza w ciągu ostatnich 4-12 tygodni.
- •Rak wątroby został potwierdzony w badaniach i operacja zakończyła się całkowitym usunięciem guza (bez widocznych pozostałości).
- •Nie ma dowodów na powrót choroby w ciągu 4 tygodni przed rozpoczęciem badania.
- •Nie stwierdzono naciekania na główne żyły w wątrobie.
- •Rak nie rozprzestrzenił się poza wątrobę.
- •Pacjent w pełni wyzdrowiał po operacji w ciągu 4 tygodni przed rozpoczęciem badania.
✗ Disqualifies
- •Pacjent leczony jednocześnie innymi metodami (np. operacja i ablacja).
- •Pacjent leczony jednocześnie innymi lekami.
- •Pozostałości guza po operacji (niecałkowite usunięcie).
Simplified criteria — AI translation
Trial details
- Minimum age
- 21 Years
- Maximum age
- 90 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
National University Hospital Singapore
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Changi General Hospital
Singapore, Singapore
Sengkang General Hospital
Singapore, Singapore
Trial contact
Pierce CHOW, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.